secwatch.observer — SEC 8-K summary
======================================

Issuer:     Altimmune, Inc. (ALT)
CIK:        0001326190
Form:       8-K
Filed at:   2022-09-14T23:59:59+00:00
Accession:  0001558370-22-014392
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Altimmune Phase 1b pemvidutide: 68.5% liver fat reduction, 4.9% weight loss at 12 weeks
--------------------------------------------------------------------------------

- At 1.8 mg dose, relative liver fat reduction of 68.5%; 94.4% of subjects achieved ≥30% reduction.
- Mean weight loss of 4.9% in non-diabetic subjects (placebo-adjusted 4.7%) at 1.8 mg dose.
- 55.6% of subjects at 1.8 mg achieved liver fat normalization (≤5%).
- No serious or severe adverse events; 2 discontinuations due to GI intolerance.
- Serum ALT declined >17 IU/L in subjects with baseline ALT ≥30 IU/L; no clinically significant ALT elevations.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1326190/000155837022014392/0001558370-22-014392-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1326190/000155837022014392/alt-20220914x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-22-014392

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer